David Hanna is an associate in the Life Sciences Group in the Litigation Department, where he focuses on biologic drug patent and Hatch-Waxman patent litigation. David’s biologics drug patent litigation experience includes litigating matters relating to Avastin® (bevacizumab) and Herceptin® (trastuzumab). David has represented both patentees and generic filers in Hatch-Waxman litigation. He has litigated matters relating to Imbruvica® (ibrutinib), Xarelto® (rivaroxaban), Suboxone® (buprenorphine naloxone), Pradaxa® (dabigatran etexilate), Ultiva® (remifentanil hydrochloride), Daytrana® (methylphenidate), Dymista® (azelastine HCl/fluticasone propionate), Epaned® (enalapril maleate), and Brisdelle® (paroxetine).
While in law school, David worked for the University of Minnesota’s Office for Technology Commercialization, where he performed patent searches relating to biotech and chemical technologies and assessed the technologies and their commercial potential in their respective markets.
Prior to joining Proskauer, David worked as an associate at Wilson, Sonsini, Goodrich, & Rosati, where he specialized in Hatch-Waxman patent litigation. He has also worked at an intellectual property law firm, where he prosecuted and litigated chemical and mechanical device patents.
In the top law firm directory The Legal 500 US, a client recommended David, noting his client service for being “super responsive and very detail oriented.”